<DOC>
	<DOCNO>NCT00000708</DOCNO>
	<brief_summary>To compare safety effectiveness fluconazole ( FCZ ) amphotericin B ( AMB ) , alone combination flucytosine ( FLC ) , treatment acute cryptococcal meningitis patient treat previously relapse previous successful treatment . Cryptococcal meningitis important cause disease death among patient AIDS . Usually AMB give either alone FLC patient infection , treatment always effective toxic effect . Animal study preliminary study humans show FCZ active cryptococcal meningitis suggest may less toxic either AMB FLC .</brief_summary>
	<brief_title>Multi-center Comparison Fluconazole ( UK-49,858 ) Amphotericin B Treatment Acute Cryptococcal Meningitis</brief_title>
	<detailed_description>Cryptococcal meningitis important cause disease death among patient AIDS . Usually AMB give either alone FLC patient infection , treatment always effective toxic effect . Animal study preliminary study humans show FCZ active cryptococcal meningitis suggest may less toxic either AMB FLC . Patients accept study randomly assign FCZ AMB . Patients assign FCZ take FCZ mouth daily 10 week . Patients assign AMB give intravenous injection AMB daily 6-10 week . Non-AIDS patient assign AMB also take FLC mouth daily . The use FLC patient AIDS decide individual basis . Patients AIDS respond satisfactorily FCZ receive maintenance therapy prevent relapse additional 12 month . Patients AIDS respond AMB may qualify another Pfizer Central Research protocol . Patients without AIDS respond therapy observe 6 month relapse . During therapy , sample blood cerebrospinal fluid ( lumbar puncture ) take periodically order evaluate effectiveness drug treatment identify possible toxic effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Immunosuppressant therapy . Cyclosporin plasma concentration monitor appropriate dosage adjustment make used amphotericin B fluconazole . Antiviral therapy . Prophylaxis Pneumocystis carinii pneumonia . Treatment intercurrent opportunistic infection long investigational agent , approve agent investigational indication , use . Antipyretics , hydrocortisone , meperidine prevent ameliorate side effect associate amphotericin B. Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Patients must : Written informed consent obtain patient patient 's legal guardian . One following : ( 1 ) Tentative identification Cryptococcus neoformans culture lumbar cerebrospinal fluid ( CSF ) . Results baseline culture need available therapy begin , therapy discontinue baseline CSF culture later find negative C. neoformans , ( 2 ) Clinical CSF finding ( cell count , protein , glucose ) compatible cryptococcal meningitis plus one following : ( ) Positive CSF India ink examination , ( b ) Culture biopsy evidence extraneural cryptococcal infection , ( c ) Positive serum CSF cryptococcal antigen test , increase titer previously treat patient suspect relapse , ( ) Biopsy evidence central nervous system cryptococcal infection . Treatment status either prior systemic antifungal therapy cryptococcosis relapse prior therapy . The success prior therapy must document negative CSF culture end therapy . Prior Medication : Allowed within 4 week study entry : Successful prior therapy cryptococcosis , 1 mg/kg/week amphotericin B . Allowed : Immunosuppressant therapy . Antiviral therapy . Prophylaxis Pneumocystis carinii pneumonia . Exclusion Criteria Coexisting Condition : Excluded : Acute chronic meningitis base etiology cryptococcosis . History allergy intolerance imidazole , amphotericin B . Moderate severe liver disease define one following : SGOT SGPT &gt; 5 x upper limit normal , total bilirubin &gt; 2.5 mg/dl , prothrombin time &gt; 5 second control , alkaline phosphatase &gt; 2 x upper limit normal . Comatose patient . Concurrent Medication : Excluded : Drugs low therapeutic ratio undergo hepatic metabolism may use fluconazole possible drug interaction clarify . Coumarintype anticoagulant . Oral hypoglycemics . Barbiturates . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Systemic antifungal agent assign study drug . Concurrent Treatment : Excluded : Lymphocyte replacement . Prior Medication : Excluded within 4 week study entry : More 1 mg/kg/week amphotericin B . Patients unlikely survive 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1991</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Cryptococcus neoformans</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>